Plain-English translation of NCT07636044 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is looking at how people with systemic lupus erythematosus (SLE, or lupus) respond to a shingles vaccine called Shingrix. Researchers want to understand whether the vaccine works as well in lupus patients as it does in people without autoimmune diseases. They'll do this by comparing blood test results from both groups after the vaccine doses.
People with lupus have weakened immune systems due to their disease and the medications they take to treat it. This means vaccines may not work as well for them. Understanding how this shingles vaccine performs in lupus patients will help doctors know whether it's a good protection option and whether lupus patients need different dosing or monitoring.
You likely qualify if…
You likely don't qualify if…
You would receive two doses of the shingles vaccine (Shingrix) as scheduled, which is the standard treatment. Researchers would then draw blood samples at specific times to measure how well your immune system responded to the vaccine. Your results would be compared to a matched group of people without lupus to understand whether the vaccine worked differently for you.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
South Korea
Seoul National University Hospital
Enrollment target
~80 participants
Started
October 2024
Primary completion
October 2030
Age range
50 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Jin Kyun Park, MD
Seoul National University Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.